2-Hydroxypropyl-β-cyclodextrin reduces retinal cholesterol in wild-type and Cyp27a1^-/- Cyp46a1^-/- mice with deficiency in the oxysterol production.

ABSTRACT:

Background and purpose

2-Hydroxypropyl-β-cyclodextrin (HPCD) is an FDA approved vehicle for drug delivery and an efficient cholesterol-lowering agent. HPCD was proposed to lower tissue cholesterol via multiple mechanisms including those mediated by oxysterols. CYP27A1 and CYP46A1 are the major oxysterol-producing enzymes in the retina that convert cholesterol to 27- and 24-hydroxycholesterol, respectively. We investigated whether HPCD treatments affected the retina of wild-type and Cyp27a1^-/- Cyp46a1^-/- mice that do not produce the major retinal oxysterols.

Experimental approach

HPCD administration was either by i.p., p.o. or s.c. Delivery to the retina was confirmed by angiography using the fluorescently labelled HPCD. Effects on the levels of retinal

SUBMITTER: El-Darzi N 

PROVIDER: S-EPMC8767317 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature